AVITA Medical Inc (AVHHL) (Q3 2026) Earnings Call Highlights: Revenue Surges 53%
AVITA Medical Inc reported Q3 2026 revenue of $26.1M, up 53% YoY, with U.S. Resell revenue rising 20% sequentially. Gross margin expanded to 84%, and operating expenses remained flat. Full-year revenue guidance was raised to $92M-$94M. Q3 growth may have included $1M from seasonal factors, and Q4 guidance suggests potential deceleration. The company expects cash flow breakeven in Q4 and flat operating expenses in 2027, with growth driven by new reimbursement frameworks and product adoption.
How this was made

The 30-second read
Why it matters
Earnings beat and guidance raise are likely to attract short‑term buying interest.
Market read
First report of earnings with strong numbers; micro‑cap but material for traders focused on healthcare small caps.
What to watch
Potential margin pressure from lower‑margin product mix and flat international revenue.
Background
AVITA Medical Inc (AVHHL) reported its Q3 2026 earnings, highlighting revenue surge, margin expansion, and upgraded guidance.
Ticker impact
Q3 2026 earnings call disclosed 53% YoY revenue growth to $26.1M, 84% gross margin, and raised full-year guidance to $92-$94M.
likely upside as market prices in revenue beat and raised guidance
Revenue and margin beat, cash use down, and guidance raised indicate improved fundamentals.
Market effects
Positive signal for medical device and wound-care sector as growth accelerates.
U.S. market may see modest buying pressure in small-cap healthcare stocks.
Limited to niche medical‑technology segment.
Counterpoint
Seasonal boost may not repeat; guidance still modest, so upside could be limited.
Key entities
- companyAVITA Medical Inc
Medical device maker reporting Q3 2026 results.
- executiveKerry Vance
CEO providing commentary on growth drivers.

